Payment overview · 2025
General Payments
$1,176.55
50 reported records · 13 companies
Healthcare provider profile · identity verified
Ravi Kumar, FNP
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner · LAS VEGAS, NV · NPI 1679270177
Verified facts
What the public records show
CMS Open Payments records show Ravi Kumar, FNP received $1,176.55 in general payments during 2025 across 50 reported records.
Salix Pharmaceuticals, a division of Bausch Health US, LLC accounted for 26.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 24 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Mounjaro, Relistor.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Farxiga by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Mounjaro by this doctor in 2024.
Salix Pharmaceuticals, a division of Bausch Health US, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported RELISTOR as an associated drug or biological on 23206 records involving 6246 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Relistor by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $305.84 | 26.0% | 16 | 2025 |
| Forte Bio-Pharma LLC | Unresolved — no canonical attribution shown | $231.58 | 19.7% | 8 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $177.36 | 15.1% | 4 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $150.65 | 12.8% | 6 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $90.49 | 7.7% | 4 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $59.50 | 5.1% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $53.53 | 4.5% | 3 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $19.38 | 1.6% | 1 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $18.75 | 1.6% | 1 | 2025 |
| Impel Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $18.73 | 1.6% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $18.32 | 1.6% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $17.19 | 1.5% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $15.23 | 1.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,176.55 | 50 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| RELISTOR Normalized: relistor |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $305.84 | 16 | 2025 |
Source payment records
|
|||||
| NALOCET Normalized: nalocet |
Drug | Forte Bio-Pharma LLC | $231.58 | 8 | 2025 |
Source payment records
|
|||||
| PROLATE Normalized: prolate |
Drug | Forte Bio-Pharma LLC | $231.58 | 8 | 2025 |
Source payment records
|
|||||
| TANLOR Normalized: tanlor |
Drug | Forte Bio-Pharma LLC | $231.58 | 8 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $150.65 | 6 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $150.65 | 6 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $143.70 | 2 | 2025 |
Source payment records
|
|||||
| TRULANCE Normalized: trulance |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $103.69 | 5 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $68.00 | 3 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $59.50 | 3 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $37.37 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $36.77 | 2 | 2025 |
Source payment records
|
|||||
| BOTOX Normalized: botox |
Biological | ABBVIE INC. | $23.82 | 1 | 2025 |
Source payment records
|
|||||
| ABILIFY ASIMTUFII Normalized: abilify asimtufii |
Drug | Otsuka America Pharmaceutical, Inc. | $22.49 | 1 | 2025 |
Source payment records
|
|||||
| ABILIFY MAINTENA Normalized: abilify maintena |
Drug | Otsuka America Pharmaceutical, Inc. | $22.49 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $19.38 | 1 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $18.75 | 1 | 2025 |
Source payment records
|
|||||
| TRUDHESA Normalized: trudhesa |
Drug | Impel Pharmaceuticals LLC | $18.73 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $17.19 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $16.16 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $15.48 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $15.23 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $15.23 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $13.55 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 28 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 30 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| RELISTOR relistor |
2025 | Relistor | 2024 | 19 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
28 | 11 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC Exact reporting entity; no affiliate inference |
2025 | RELISTOR open payments reported associated product |
CMS Open Payments — General Payments 23206 supporting records · 6246 recipient NPIs · example record 1231775437 |
Relistor · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 558 | 211 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 437 | 142 |
| Gabapentin | Gabapentin | 241 | 88 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 229 | 77 |
| Oxycodone Hcl | Oxycodone Hcl | 205 | 67 |
| Morphine Sulfate Er | Morphine Sulfate | 171 | 56 |
| Ibuprofen | Ibuprofen | 106 | 35 |
| Alprazolam | Alprazolam | 103 | 27 |
| Pregabalin | Pregabalin | 98 | 41 |
| Tizanidine Hcl | Tizanidine Hcl | 88 | 31 |
| Meloxicam | Meloxicam | 86 | 31 |
| Diclofenac Sodium | Diclofenac Sodium | 81 | 42 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 76 | 26 |
| Atorvastatin Calcium | Atorvastatin Calcium | 76 | 33 |
| Amlodipine Besylate | Amlodipine Besylate | 61 | 31 |
| Zolpidem Tartrate | Zolpidem Tartrate | 57 | 15 |
| Metformin Hcl | Metformin Hcl | 50 | 24 |
| Diazepam | Diazepam | 46 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 44 | 20 |
| Methocarbamol | Methocarbamol | 42 | 17 |
| Naproxen | Naproxen | 42 | 16 |
| Methadone Hcl | Methadone Hcl | 40 | 15 |
| Amitriptyline Hcl | Amitriptyline Hcl | 35 | 15 |
| Baclofen | Baclofen | 35 | 18 |
| Fluticasone Propionate | Fluticasone Propionate | 35 | 18 |
| Lisinopril | Lisinopril | 35 | 16 |
| Trazodone Hcl | Trazodone Hcl | 35 | 14 |
| Oxycontin | Oxycodone Hcl | 32 | suppressed |
| Mounjaro | Tirzepatide | 30 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 28 | 11 |
| Losartan Potassium | Losartan Potassium | 27 | 15 |
| Xtampza Er | Oxycodone Myristate | 23 | suppressed |
| Famotidine | Famotidine | 20 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 20 | suppressed |
| Nifedipine Er | Nifedipine | 20 | 14 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 19 | suppressed |
| Relistor | Methylnaltrexone Bromide | 19 | suppressed |
| Azithromycin | Azithromycin | 18 | 15 |
| Hydrochlorothiazide | Hydrochlorothiazide | 17 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 17 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 17 | suppressed |
| Ondansetron Odt | Ondansetron | 16 | suppressed |
| Naloxone Hcl | Naloxone Hcl | 15 | 14 |
| Potassium Chloride | Potassium Chloride | 15 | suppressed |
| Furosemide | Furosemide | 14 | suppressed |
| Movantik | Naloxegol Oxalate | 14 | suppressed |
| Lidocaine | Lidocaine | 13 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 12 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 12 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 12 | suppressed |
| Butalbital-Aspirin-Caffeine | Butalbital/Aspirin/Caffeine | 11 | suppressed |
| Jardiance | Empagliflozin | 11 | suppressed |
| Topiramate | Topiramate | 11 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,176.55 · 50 records | Salix Pharmaceuticals, a division of Bausch Health US, LLC | ABILIFY ASIMTUFII, ABILIFY MAINTENA, AIRSUPRA, BOTOX, BREZTRI, Dexcom G6 Transmitter, FARXIGA, Kerendia, Korlym, MOUNJARO, NALOCET, NURTEC ODT, PROLATE, QULIPTA, RELISTOR, REXULTI, TANLOR, TRUDHESA, TRULANCE, UBRELVY, VRAYLAR, YUPELRI, ZAVZPRET, ZEPBOUND | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error